Public Accountability Report Public Accountability Report

2025 Disease Control
Mission Statement The Office of Disease Control (ODC) is committed to protecting Illinois residents from infectious diseases and advancing health equity by collaborating with IDPH offices, local health departments, and community partners to prevent disease and reduce health disparities through monitoring, testing, evaluation, immunization, surveillance, grant-making, and evidence-based community programs.
Program Goals and Objectives
  1. The ODC’s goals are to:
    1. identify cases for investigation;
    2. estimate the magnitude of diseases;
    3. perform diagnostic testing for outbreak response;
    4. evaluate response and prevention measures;
    5. monitor changes in infectious agents;
    6. facilitate research;
    7. measure the impacts of changes in health-care practices;
    8. identify target populations and develop the most effective interventions; and
    9. assess providers and consider possible quality improvement measures in underserved areas and at-risk populations.
Source of Funds General Revenue Fund, State Coronavirus Urgent Remediation Emergency Fund, African-American HIV/AIDS Response Fund Statutory Authority 20 ILCS 2310
Fiscal Year 2026 Target/Projected Fiscal Year 2025 Actual Fiscal Year 2025 Target/Projected Fiscal Year 2024 Actual Fiscal Year 2023 Actual
Input Indicators
Total expenditures - all sources (in thousands) $ 965,363.1 $ 361,226.0 $ 1,115,108.4 $ 347,220.9 $ 427,005.5
Total expenditures - state appropriated funds (in thousands) $ 965,363.1 $ 361,226.0 $ 1,115,108.4 $ 347,220.9 $ 427,005.5
Average monthly full-time equivalents 300.0 290.0 275.0 255.0 243.0
Output Indicators
Number of underserved, foreign-born Asian and African immigrants, refugees, and persons who use drugs provided education on hepatitis B and referred for screening, vaccination, and treatment services 500.0 608.0 500.0 N/A N/A
Hepatitis Prevention Program (HP) - number of individuals referred for screenings 6,000 685.0 6,000 7,787 6,644
HP - number of hepatitis B screenings administered 800.0 279.0 800.0 764.0 688.0
HP - number of individuals in group outreach and education events 60,000 60,385 60,000 156,704 99,009
Number of HCV tests performed by grantees 2,750 2,011 2,750 2,861 2,808
Number of HIV-positive tests performed by the grantee (direct) 20.0 4.0 75.0 77.0 15.0
Number of HIV-positive tests performed by the grantee (regional) 50.0 45.0 40,000 37,491 29,426
Outcome Indicators
Number of GC/CT samples received 25,908 24,037 22,757 22,301 22,271
Number of GC/CT samples rejected 212.0 197.0 207.0 229.0 130.0
Number of GC/CT samples tested 25,696 23,840 22,550 21,905 22,141
Number of GC/CT-positive specimens identified from testing 2,124 2,226 3,188 2,333 2,540
Prevalence of GC/CT in tested population 8.22% 9.33% 14.14% 10.72% 11.00%
Average turnaround time for reporting GC/CT results (in days) 2.0 2.0 2.0 2.0 2.0
Number of Grade A Dairy samples received 2,652 2,294 N/A 2,489 N/A
Number of Grade A Dairy samples rejected 28.0 42.0 N/A 18.0 N/A
Number of Grade A Dairy samples tested 2,620 2,252 N/A 2,471 N/A
Number of Grade A Dairy specimens identified with biological or chemical contaminates 140.0 118.0 N/A 123.0 N/A
Prevalence of Grade A Dairy contaminates in tested population (a) 13.63% 4.69% N/A 6.47% N/A
Average turnaround time for reporting Grade A Dairy results (in days) 3.0 3.0 2.0 5.0 N/A
Number of HIV samples received 9,912 8,452 6,721 7,343 6,654
Number of HIV samples rejected 53.0 74.0 158.0 129.0 48.0
Number of HIV samples tested 9,858 8,378 6,563 7,129 6,606
Number of HIV-positive specimens identified from testing 72.0 84.0 109.0 120.0 107.0
Prevalence of HIV in tested population 0.72% 1.00% 1.66% 1.72% 2.00%
Average turnaround time for reporting HIV results (in days) 2.0 2.0 2.0 2.0 2.0
Number of NBS samples received 145,723 145,074 N/A 144,217 N/A
Number of NBS samples rejected 373.0 318.0 N/A 263.0 N/A
Number of NBS samples tested (samples received - samples rejected) 145,350 144,756 N/A 143,954 N/A
Number of disorders on the NBS test panel 260.0 258.0 N/A 214.0 N/A
Total NBS tests performed (b) 9,447,880 9,334,419 3,170,208 9,226,368 3,062,602
Number of NBS disorders identified from testing 23,548 20,663 21,788 18,070 19,430
Prevalence of NBS disorders in tested population (number of disorders identified / total number of samples tested) 0.25% 0.22% 0.69% 0.20% 0.63%
Average turnaround time for reporting NBS results (in days) 6.9 7.3 8.0 7.6 7.2
Number of private water samples received 3,848 4,512 4,140 4,080 4,098
Number of private water samples rejected 482.0 492.0 582.0 477.0 499.0
Number of private water samples tested 3,367 4,020 3,558 3,603 3,599
Number of private water specimens identified with bacterial contaminates 1,337 1,580 1,641 1,446 1,531
Prevalence of private water contaminates in tested population 36.69% 37.00% 46.12% 38.18% 43.00%
Average turnaround time for reporting private water results (in days) 1.0 1.0 6.0 3.0 3.0
Number of syphilis samples received 10,184 8,683 7,273 7,399 7,222
Number of syphilis samples rejected 63.0 80.0 133.0 134.0 71.0
Number of syphilis samples tested 10,126 8,603 7,140 7,175 7,151
Number of syphilis-positive specimens identified from testing 981.0 934.0 864.0 861.0 811.0
Prevalence of syphilis in tested population 9.64% 10.83% 12.10% 12.00% 11.00%
Average turnaround time for reporting syphilis results (days) 2.0 2.0 2.0 2.0 2.0
HP - number of individuals referred for hepatitis treatment 100.0 102.0 100.0 181.0 176.0
Harm Reduction Community Linkages Project (HRCL) - number of linkages to prevention, treatment, and harm reduction services for individuals with opioid use disorder (OUD), including prescription opioids as well as illicit drugs such as heroin 2,000 823.0 900.0 N/A N/A
Footnotes
The fiscal year 2026 projection is based on collective data from fiscal year 2024 and fiscal year 2025. Based on historical numbers, and the fact that contamination events have increased with lower sample numbers, it is reasonable to predict that the prevalence with increase in fiscal year 2026. As these initial projections were put forth at the end of fiscal year 2023 and were new metrics for fiscal year 2024, the addition of data using the newly approved GOMB metrics will undoubtedly present discrepancies from the original projections. In fiscal year 2024, the Division of Laboratories began reporting on new metrics submitted to and approved by GOMB at the end of fiscal year 2023. However, we were still required to provide fiscal year 2025 and 2025 projections for these new metrics. As these were new metrics that were never reported on before, all metrics were “best guesses” at the time and subject to change. In Q3 of fiscal year 2025, a new disorder was added to the NBS panel. The previous projection for fiscal year 2025 was not based on the addition of any new disorders added to the Recommended Uniform Screening Panel (RUSP) or through a legislative act. As these initial projections were first put forth at the end of fiscal year 2023 and were new metrics for fiscal year 2024, the addition of data using the newly approved GOMB metrics will undoubtedly present discrepancies from the original projections provided.

Looking for more information?